Nubratori RX, began just after the enactment by Congress, of the Drug Quality and Security Act of 2013. Nubratori RX spent its first four years in research and development, testing, and validating potential new products as requested by healthcare providers. 2017 brought the launch of Nubratori RX’s first production run. To date, Nubratori RX has produced over 250,000 units of medications and counting, with zero adverse reports. Emerging successfully from the COVID-19 pandemic, Nubratori RX is looking to double its existing business and continues to proudly serve patients, healthcare providers, pharmacies, hospitals and clinics.

 

Nubratori RX, under its FDA Registration for Outsourcing Facilities, compounds and manufactures cGMP sterile and non-sterile medications requested by providers when they have made a determination there is a clinically significant difference to meet the patient's needs over other commercially available products on the market. 

 

If you are a hospital administrator, pharmacist, healthcare provider or physician and would like to find out more, please contact us.